 |
|
The Use of Statins in Conjunction With Protease Inhibitors and in Renal Insufficiency—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In reply
We thank Drs Mikhail and Cope for pointing out the importance of the potential drug interactions between statins and protease inhibitors, particularly ritonavir, which is a potent inhibitor of cytochrome (CY) P3A4. However, in addition to the 2 cases of rhabdomyolysis due to probable interaction with simvastatin and ritonavir that were referenced, an additional case of rhabdomyolysis due to atorvastatin and delavirdine has been reported in an individual receiving 20 mg of atorvastatin.1 The most common clinical abnormality associated with ritonavir use is a marked elevation in triglyceride levels that cannot be controlled by statin monotherapy, and clearly this patient population merits further investigation. A recent review of the new lopinavir-ritonavir formulation notes that there were no clinically significant interactions with pravastatin, which is not metabolized through the CYP3A4 system, nor were there expected to be interactions with fluvastatin, which also is not metabolized through the CYP3A4 system.2 . . . [Full Text of this Article]
RELATED ARTICLE
The Use of Statins in Conjunction With Protease Inhibitors and in Renal Insufficiency
Nasser Mikhail and Dennis Cope
Arch Intern Med. 2003;163(13):1615-1616.
EXTRACT
| FULL TEXT
|
